Addison Whitney Contributes To Three New Pharmaceutical Brands Approved by the FDA
Addison Whitney announced today that the United States Food and Drug Administration has approved three new pharmaceutical drugs. The global brand consulting firm consulted on the development of the proprietary names for all three assets. Services rendered varied from brand development to name validation studies used in white paper documents, written by Addison Whitney, for submission to the regulatory agencies.Client: Kamada
Brand Name: Glassia™ (alpha 1 proteinase inhibitor)
Indication: Treatment of alpha 1 antitrypsin deficiency (AATD)
Client: Purdue Pharma L.P.
Brand Name: Butrans™ (buprenorphine) Transdermal System CIII
Indication: Management of moderate to severe chronic pain
Client: Strativa Pharmaceuticals
Brand Name: Zuplenz™ (ondansetron)
Indication: Prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting
"As a leading healthcare branding firm we're always excited to hear about the successes our clients have in getting their assets approved. To have three assets approved, in less than a week from each other, is a testament to the years of experience and expertise our consulting and creative teams have in developing customized brand names while balancing the legal and regulatory realities our industry faces" said Vince Budd, Senior Vice President.
About Addison Whitney
Addison Whitney is a global, full-service brand consulting firm. Founded in 1991, the firm offers branding expertise in the areas of verbal branding, visual branding, brand strategy, and research and analysis. Clients come to Addison Whitney from industries including: consumer, technology, business to business, financial, hospitality and other market segments. Addison Whitney health, a specialized healthcare division of Addison Whitney, serves the branding needs of pharmaceutical, biotechnology, life science, and medical specialties. For more information, visit www.addisonwhitney.com.
For more information please contact Lizzy Guterma at 704-697-4055 orlizzy.guterma@addisonwhitney.com.
« BACK TO PRESS RELEASES
